Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to the recommended phase 2 dose.

IF 2.7 4区医学 Q3 ONCOLOGY

Cancer Chemotherapy and Pharmacology Pub Date : 2024-09-01 DOI:10.1007/s00280-023-04595-8

Bart A Jessen, Paul Cornwell, Sean Redmond, Thomas Visalli, Marie Lemper, Todd Bunch, Timothy Hart

引用次数: 0

Abstract Image

查看原文本刊更多论文

更正：IQ联盟对肿瘤学小分子首次患者试验起始剂量选择的分析表明，一种基于NOAEL的替代方法是安全的，同时可以将时间缩短到推荐的2期剂量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Chemotherapy and Pharmacology 医学-药学

CiteScore

6.10

自引率

3.30%

发文量

116

审稿时长

2.5 months

期刊介绍： Addressing a wide range of pharmacologic and oncologic concerns on both experimental and clinical levels, Cancer Chemotherapy and Pharmacology is an eminent journal in the field. The primary focus in this rapid publication medium is on new anticancer agents, their experimental screening, preclinical toxicology and pharmacology, single and combined drug administration modalities, and clinical phase I, II and III trials. It is essential reading for pharmacologists and oncologists giving results recorded in the following areas: clinical toxicology, pharmacokinetics, pharmacodynamics, drug interactions, and indications for chemotherapy in cancer treatment strategy.